Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05261360
Other study ID # 56733164/203
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 2022
Est. completion date March 2025

Study information

Verified date March 2022
Source Eskisehir Osmangazi University
Contact Ayla Eker Sariboyaci, AssocProfDr.
Phone +905382696420
Email aylaekersariboyaci@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.


Description:

Mesenchymal stem cell-derived exosomes will be developed and patented as an advanced technology platform as an autologous treatment protocol to repair damaged cartilage tissue. The fact that this treatment is obtained from an autologous source will significantly contribute to the literature in the field of personalized therapy (personalized medicine) and will pave the way for discoveries. Experiences from clinical trials may guide the use of MSC exosomes in other tissue and cell damaged pathologies and immune pathologies or chronic inflammatory diseases. This study was supported by a grant (1004, 20AG031) from The Scientific and Technological Research Council of Turkey (TUBITAK).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2025
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 50 Years
Eligibility Inclusion Criteria: - Accepting the Informed Consent Form - Degenerative meniscus damage grade 1, 2 or 3 on MRI in both right and left knees, and also the patient does not want surgical treatment - Patients with the same degenerative meniscus grade in both knees - Patients with ongoing pain - Patients without a history of malignancy - Absence of signs of unstable meniscus tear such as snagging or locking - Patients with stage 0, 1 or 2 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging - Patients without lower extremity malalignment Exclusion Criteria: - Patients whose treatment method was explained and who did not accept the method - Patients outside the working-age range - Congenital lesion - Patients requiring surgical treatment (e.g. bucket handle tear and locked knee) - Active inflammatory or connective tissue disease is thought to affect the patient's pain (eg lupus, rheumatoid arthritis, fibromyalgia) - Local or systemic infection - Pregnant or breastfeeding women - Active endocrine disorder that may affect the assessment of patient's pain (eg, hypothyroidism, diabetes) - Active neurological disorder that may affect the assessment of the patient's pain (eg, peripheral neuropathy, multiple sclerosis) - Active heart disease - Presence of a pacemaker - Conditions where MR-I is contraindicated - Patients with stage 3 or 4 gonarthrosis according to Kellgren-Lawrence gonarthrosis staging - Patients with lower extremity malalignment - Patients with signs of unstable meniscus tear such as snagging or locking

Study Design


Intervention

Drug:
SF-MSC-EX
Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
SF-MSC
Intra-articular administration of synovial fluid-derived mesenchymal stem cells

Locations

Country Name City State
Turkey Eskisehir Osmangazi University Eskisehir

Sponsors (2)

Lead Sponsor Collaborator
Eskisehir Osmangazi University The Scientific and Technological Research Council of Turkey

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. — View Citation

Pan H, Zhang P, Zhang Z, Yang Q. Arthroscopic partial meniscectomy combined with medical exercise therapy versus isolated medical exercise therapy for degenerative meniscal tear: A meta-analysis of randomized controlled trials. Int J Surg. 2020 Jul;79:222-232. doi: 10.1016/j.ijsu.2020.05.035. Epub 2020 Jun 6. Review. — View Citation

Tegner Y, Lysholm J. Rating systems in the evaluation of knee ligament injuries. Clin Orthop Relat Res. 1985 Sep;(198):43-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Knee Functions The functional evaluation of the participants will be evaluated on the Tegner-Lysholm knee scoring scale. In Tegner-Lysholm knee scoring, examinations for the knee joint (Limp, support, pain, instability, locking, swelling, stair-climbing, and squatting) will be evaluated, and a maximum of 100 and a minimum of 0 points will be given. According to the evaluation, <65 points are interpreted as bad, 65-83 points as fair, 84-90 points as good, >90 points as excellent. Scores will be recorded by being examined before treatment and at the 6th, and 12th months after treatment. Knee functions of the control group will be evaluated simultaneously, and the effects of treatments on knee function will be determined. Up to 12th months
Primary Evaluation of Physical Activity The physical activity evaluation of the participants will be evaluated with the IPAQ (international physical activity questionnaire) short form. IPAQ short form will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The control group's physical activity will be evaluated simultaneously, and the effects of treatments on physical activity will be determined. Up to 12th months
Primary Evaluation of Pain Pain assessment of the participants will be evaluated with VAS (Visual analog scale). The VAS will be evaluated and recorded before treatment and at the 6th, and 12th months after treatment. The physical activity of the control group will be evaluated simultaneously, and the effects of treatments on pain will be determined. Up to 12th months
Primary Evaluation of Radiological Images Participants will receive knee x-ray imaging and knee magnetic resonance imaging before treatment. The same radiological imaging will be performed at the 6th and 12th months after the treatment. At the same time, the same radiological imaging will be performed on the control group, and the effects of treatments on radiological imaging will be evaluated. Up to 12th months
Primary Evaluation of Cytokine Levels and Cytokine Genes Analyzes Before treatment and at the 6th and 12th months after treatment, cytokine levels (IL-10, IL-6, TNF-a, IL-8, IL-1ß, IFN-?, IL-2, IL-4, IL-13, MCP-1, VEGF) and gene analyzes (IL-10, IL-6, TNF-a, IL-8, IL-1ß, IFN-?, IL-2, IL-4, IL-13, MCP-1, IL-1ra, MIP-1b, CTGF, TGFß3, BMP-2, BMP-4, IGF-1, IGF-2, PDGF, EGF, and VEGF genes) will be checked in the samples taken from the synovial fluid and blood. Samples will be taken from the control group along with the treatment group. In this way, the effects of treatments on cytokine levels will be evaluated. Up to 12th months
Primary Evaluation of Edema Edema in both knees will be measured using a tape measure by marking the midpoints of both patellae. Pre-treatment measurements will be recorded. Measurements of both knees will be recorded at 6 months and 12 months after treatment. The knees of the patients not receiving treatment will be measured simultaneously, and the changes will be compared. Up to 12th months
Primary Evaluation of Knee Joint Range of Motion The range of motion of both knees will be measured using the "Baseline Digital Absolute+Axis Goniometer." Knee extension measurements will be made with the patient in the supine position and flexion in the prone position. Pre-treatment measurements will be recorded. Post-treatment 6th and 12th-month measurements will also be recorded. Measurements of patients not receiving treatment will be recorded simultaneously, and changes will be compared. Up to 12th months
Primary Monitoring of treatment-related complications Adverse effects and complications will be observed in the treatment group, except for the expected local reactions (redness, swelling, bruising, etc.) after the application. Up to 12th months
See also
  Status Clinical Trial Phase
Recruiting NCT04554212 - Blood Flow Restriction Training After Patellar INStability N/A
Completed NCT04815980 - Impact of Pilates on Running Mechanics N/A
Not yet recruiting NCT05484778 - Analysis of Balance and Functional Hop Tests Used for Return to Sports in Athletes With Lower Extremity Injuries by Dual Task Study N/A
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4
Completed NCT02540811 - Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament N/A
Recruiting NCT03755388 - Clinical Trial of an MRI Based Patient Specific Focal Knee Resurfacing Implant N/A
Recruiting NCT00174213 - Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound Phase 1
Completed NCT03202901 - Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers N/A
Completed NCT06206018 - Patient-Reported Outcome Measures in Lower Extremity Rehabilitation Program PROM_R: Impact on Health Care N/A
Completed NCT04543227 - Opioid Laws and Pediatric Use
Completed NCT06078072 - Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions
Completed NCT04956393 - The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study N/A
Recruiting NCT06451510 - Knee Osteoarthritis in the Region of Norrbotten
Completed NCT04118023 - 7T MRI to Evaluate Cartilage Defects in the Knee
Completed NCT03486405 - A Randomized Control Trial: Returning to Run After Injury N/A
Recruiting NCT03858231 - Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery Phase 4
Recruiting NCT02918734 - Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws N/A
Suspended NCT02270905 - Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus N/A
Completed NCT01227694 - Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis Phase 1/Phase 2
Completed NCT00991588 - Clinical Outcome of Posterior Cruciate Ligament (PCL) Posterolateral Reconstruction